<DOC>
	<DOCNO>NCT01474356</DOCNO>
	<brief_summary>The aim randomise trial investigate whether hyperthermia ( HT ) combine interstitial brachytherapy ( ISBT ) influence local control ( LC ) , disease-free survival ( DFS ) , acute late side effect patient advanced cervical cancer . Vaginal symptom assess SOMA score , bladder rectum symptom EORTC/RTOG score . Following completion radiochemotherapy , consecutive patient cervical cancer ( FIGO stage II - III ) randomly assign two treatment group , either ISBT alone ISBT combine interstitial hyperthermia ( ISHT ) . A total 205 patient include statistical analysis . Once week , HT , temperature 42.5Â°C , administer 45 minute HDR BT . Follow-up examination schedule 6 week completion BT , every 3 month first 2 year , every 6 month throughout next 3 year . If relapse suspect , biopsy obtain patient .</brief_summary>
	<brief_title>Hyperthermia Combined Brachytherapy CCU</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Fever</mesh_term>
	<criteria>patient locally advanced cervical cancer FIGO stage II III sign informed consent participation study patient FIGO stage I IV patient poor performance status contraindication radical treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>brachytherapy</keyword>
	<keyword>interstitial hyperthermia</keyword>
	<keyword>cervical cancer</keyword>
	<keyword>side effect</keyword>
	<keyword>Locally advanced cervical cancer patient</keyword>
</DOC>